Chinese Journal of Tissue Engineering Research ›› 2014, Vol. 18 ›› Issue (14): 2257-2262.doi: 10.3969/j.issn.2095-4344.2014.14.020

Previous Articles     Next Articles

Mesenchymal stem cells in gene therapy: specialty and problems

Li Li-chun, Li Jian-ping   

  1. Liaoning Blood Center, Shenyang 110044, Liaoning Province, China
  • Received:2014-02-28 Online:2014-04-02 Published:2014-04-02
  • Contact: Li Jian-ping, Chief physician, Liaoning Blood Center, Shenyang 110044, Liaoning Province, China
  • About author:Li Li-chun, Master, Liaoning Blood Center, Shenyang 110044, Liaoning Province, China
  • Supported by:

    the Science and Technology Plan of Shenyang City, No. F10-206-1-00

Abstract:

BACKGROUND: Bone marrow mesenchymal stem cells have become a promising kind of target cells for gene therapy because of easy preparation, strong self-proliferative capacity, stable biological characteristics, low immunogenicity, long-term survival in the host brain, easy transfection by exogenous gene, high transfection efficiency, and tropism for tumor cells.
OBJECTIVE: To analyze the advantages and disadvantages of mesenchymal stem cells used in gene therapy for refractory diseases based on different gene transfer methods.
METHODS: A computer-based online retrieval was performed in PubMed database, Chinese Journal Full Text Database, Wanfang database to search papers regarding mesenchymal stem cells published from January 2000 to December 2013. The key words were “mesenchymal stem cell, gene therapy” in English and Chinese. Totally 2114 articles were retrieved, and finally, 42 articles were included in result analysis.
RESULTS AND CONCLUSION: There are a variety of gene therapies that can be divided according to gene manipulation: (1) gene correction and gene replacement; (2) gene augmentation and gene inactivation. There are two routes of administration, in vitro and in vivo. As opposed to other cells, bone marrow mesenchymal stem cells can survive in the host brain for a longer time, are easier to be transfected by exogenous genes, and has a tropism for tumor cells. Thus, bone marrow mesenchymal stem cells have become a promising kind of target cells for gene therapy. Mesenchymal stem cell as carriers of the gene therapy have been used in phase III clinical trials for the treatment of graft-versus-host disease and Crohn’s disease treatment. In China, some achievements have been harvested in mesenchymal stem cell therapy for refractory diseases. To exploring the optimal therapeutic window for stem cell transplantation, and to find the appropriate gene dosage, the number of transplanted cells and the appropriate timing of treatment are urgent to be solved.


中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程


全文链接:

Key words: stem cells, mesenchymal stem cells, gene therapy

CLC Number: